TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Quality of Decisions About Treatment of Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18+~* In the last 12 months, talked to a health care provider about starting or stopping a treatment (prescription medicine for depression or counseling)~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decision Aid (Type: EXPERIMENTAL): Group receiving the decision aid (DVD/booklet)
- Control (Type: NO_INTERVENTION): Group not receiving the decision aid (DVD/booklet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age \>12 years~2. Presence of severe or moderately severe P. falciparum malaria, with and without blackwater fever, confirmed by positive blood smear with asexual forms of P. falciparum~3. Temperature \>38 degrees Celsius on admission or fever during the preceding 24hours~4. Written informed consent from patient or attending relative able to and willing to give informed consent. Consent form and information sheets will be translated into Bangla and copies provided to the patient.~Exclusion Criteria:~1. Patient or relatives unable or unwilling to give informed consent~2. History of chronic liver disease~3. History of alcohol use (\>3drinks per day)~4. Contraindication or allergy to paracetamol or artesunate therapy~5. Contraindication to nasogastric tube insertion i.e. facial fracture, bleeding diathesis~6. Pregnancy

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: EXPERIMENTAL): \>50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~\<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
- No Paracetamol (Type: ACTIVE_COMPARATOR): No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Long-Acting Acetaminophen in Postoperative Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 17 and less than 46 years of age~* Must weigh at least 100 lbs with a body mass index of at least 18 and less than 30~* Scheduled to undergo surgical extraction of one impacted third molar from the lower jaw. The third molar from the upper jaw from the same side may also be removed.~* Experiencing moderate to severe pain after extraction of third molars.~Exclusion Criteria:~* Cannot be allergic to acetaminophen (Tylenol) or any non-steroidal anti-inflammatory drugs (e.g., Motrin, Advil, Aleve, Naproxen).~* Cannot be pregnant (or planning to be pregnant) or nursing a baby~* Unable to swallow whole large tablets or caplets.~* Cannot have any other medical conditions that the investigator feels may compromise your safety or the study results.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Acetaminophen ER (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from chronic pain of a well documented cause that requires continuous administration of opioids~* Received opioids continuously for a minimum of 7 days prior to enrollment with a projected need for continuous opioids for at least the length of the primary treatment period (15 days)~* Received the pain relief medication equivalent to at least 30 mg of oral morphine the day prior to enrollment~* Available for careful monitoring during the first 72 hours following administration of Duragesic®~* If female of child-bearing potential, must have a negative serum or urine pregnancy test within 1 week of enrollment~Exclusion Criteria:~* Patients with skin disease that precludes application of Duragesic® or which may affect the absorption of fentanyl~* Known sensitivity to fentanyl, other opioids, or adhesives~* Have a life expectancy less than the length of the primary treatment period (15 days)~* Have pain due to surgery, a clinically significant fever (i.e., above 38 C/100.4 F), a clinical condition that in the investigator's judgment prevents participation in the study (e.g., clinically significant liver or kidney dysfunction), or are currently being treated with ketoconazole, ritonavir or other disallowed concomitant therapy~* Female patients who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written consent to participate in the study~* Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions~* Male or female ≥ 40 years of age~* Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening~* Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA~* Kellgren-Lawrence (KL) Grade 2, 3 or 4 in the index knee based on X-ray performed during Screening~* Qualifying score for WOMAC A at Screening and Day 1/Baseline~* Index knee pain for \>15 days over the last month (as reported by the patient)~* Body mass index (BMI) ≤ 40 kg/m2~* Ambulatory and in good general health~* Willingness to abstain from use of protocol-restricted medications during the study~Exclusion Criteria:~* Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease~* History of infection in the index knee joint~* Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening~* Presence of surgical hardware or other foreign body in the index knee~* Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of Screening~* IA corticosteroid (investigational or marketed) in index knee within 3 months of Screening~* IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening~* IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months of Screening~* Oral corticosteroids (investigational or marketed) within 1 month of Screening~* Any other IA drug/biologic use within 6 months of Screening or 5 half-lives (whichever is longer) (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy and amniotic fluid injection)~* Prior administration of FX006~* Women of child-bearing potential not using effective contraception or who are pregnant or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FX006 32 mg (Type: EXPERIMENTAL): Single intra-articular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 and \< 75~* Cirrhotics with UGIE (Upper Gastrointestinal Endoscopy ) within last 24 hours.~Exclusion Criteria:~* Non cirrhotic~* Hepatocellular carcinoma~* Advanced cardiopulmonary disease~* Pregnancy~* Extrahepatic malignancy~* Patient on anticoagulation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard Care + NAC (N-ACETYLCYSTEINE) infusion (Type: EXPERIMENTAL): None
- Standard Care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~Inclusion criteria (selected):~* Patients (18 years or older) scheduled to undergo a primary, unilateral, elect ive total knee replacement~* Written Informed Consent~Exclusion criteria~Exclusion criteria (selected):~* Patients with an excessive risk of bleeding, for example because of history of bleeding diathesis major surgery or trauma within the last 3 months history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, arteriovenous (AV) malformation or aneurysm clinically relevant bleeding or gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days prior to joint replacement surgery or anticipated need during the study treatment period thrombocytopenia.~* Active malignant disease or current cytostatic treatment~* Known severe renal insufficiency~* Liver disease expected to have any potential impact on survival, or elevated aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 2x upper limit of normal~* Recent unstable cardiovascular disease or history of myocardial infarction within the last 3 months~* Pre-menopausal women who are pregnant or nursing, or are of child-bearing pote ntial and are not practising or do not plan to continue practising acceptable me thods of birth control~* Allergy to radio opaque contrast media or iodine, heparins (incl. heparin indu ced thrombocytopenia) or dabigatran~* Contraindications to enoxaparin~* Participation in a clinical trial during the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran etexilate 220 mg (Type: EXPERIMENTAL): 220 mg once daily
- dabigatran etexilate 150 mg (Type: EXPERIMENTAL): 150 mg once daily
- enoxaparin (Type: ACTIVE_COMPARATOR): 40 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Homozygous for the F508del CFTR mutation, genotype to be confirmed at the Screening Visit~* Confirmed diagnosis of CF defined as a sweat chloride value ≥60 mmol/L by quantitative pilocarpine iontophoresis~* Forced expiratory volume at one second (FEV1) ≥40% and ≤90% of predicted normal for age, sex, and height during screening~* Stable CF disease as judged by the investigator~* Willing to remain on a stable CF medication regimen through Week 24 or, if applicable, the Safety Follow up Visit~Exclusion Criteria:~* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant.~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 (first dose of study drug)~* Pregnant or nursing females (females of childbearing potential must have a negative pregnancy test at Screening and Day 1)~* Sexually active participants of reproductive potential who are not willing to follow the contraception requirements

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
- VX-661/IVA (Type: EXPERIMENTAL): VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥ 18 years)~* The participant is able to give informed consent.~* Established atherothrombotic cardiovascular disease (CVD) or high cardiovascular risk, of for individuals without established cardiovascular disease, a calculated 5 year CVD risk of 15% or greater (calculated using the 1991 Anderson Framingham risk equation with adjustments as defined by the New Zealand Guidelines Group recommendations)~* The trial Investigator considers that each of the polypill components are indicated~* The trial Investigator is unsure as to whether a polypill-based strategy or usual care is better.~Exclusion Criteria:~* Contraindication to any of the components of the polypill (e.g. known intolerance to aspirin, statins, or ACE inhibitors,pregnancy or likely to become pregnant during the treatment period).~* The treating doctor considers that changing a participant's cardiovascular medications would put the participant at risk (e.g. symptomatic heart failure, high dose βblocker required to manage angina or for rate control in atrial fibrillation,accelerated hypertension, severe renal insufficiency, a history of severe resistant hypertension)~* Known situation where medication regimen might be altered for a significant length of time, e.g. current acute cardiovascular event, planned coronary bypass graft operation.~* Unlikely to complete the trial (e.g. lifethreatening condition other than cardiovascular disease) or adhere to the trial procedures or attend study visits (e.g. major psychiatric condition, dementia).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- polypill (Type: EXPERIMENTAL): Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
- Usual Care (Type: ACTIVE_COMPARATOR): Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~* Black or Hispanic based on self-identification (Hispanic if identify as both)~* Male and female, ages 18-75 years~* Ability to provide informed consent~* Clinical history consistent with asthma for \> 1 year.~* Prescribed ICS as daily maintenance therapy~* Participant must also have an ACT score of 19 or less, or a history of one or more exacerbations in the past year that required patient report of systemic corticosteroid use.~EXCLUSION CRITERIA~* Life expectancy less than one year~* Known allergy to the ICS inhaler used in the study~* Having COPD or other chronic lung disease other than asthma; with the exception of the following:~  * Dx of COPD in a never smoker without any other lung disease or any other disease that might cause airway obstruction such as: Cystic Fibrosis, Connective Tissue Disease, premature birth, organ transplantation, bronchiectasis, sarcoid, and obliterative bronchiolitis~ * Dx of COPD in former smoker with normal PFTs done after the person quit smoking~ * Dx of COPD in current smoker with normal PFTs done in past 24 months~ * Dx of COPD IN CURRENT OR FORMER SMOKER with obstruction on PFTs: normal diffusing capacity in past 24 months and demonstrated reversibility of 12% or more at any time~* Regular systemic corticosteroid use daily or every other day for any reason-including asthma or other medical reasons~* Use of systemic corticosteroid, or visit to the doctor's office, emergency department (ED) or urgent care, or overnight hospitalization for an asthma exacerbation in the past month (can wait and re-check eligibility after one month)~* Use of biologics (injections or infusion medicines): with the exception of the following:~  * the patient has been on a stable dose of a biologic for at least 6 months and,~ * must have had an exacerbation at least 2 months after starting on a biologic to be considered eligible OR~ * must have a current ACT score \<=19 to be considered eligible.~* Bronchial thermoplasty less than 6 months ago (can re-check eligibility 6 months after procedure)~* Another family member living in the same household already enrolled in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PARTICS (Type: ACTIVE_COMPARATOR): addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
- Usual Care (Type: NO_INTERVENTION): Provider-enhanced usual care arm; no change in asthma management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erythromycin in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a definitive diagnosis of Parkinson's Disease (per United Kingdom brain bank criteria), Hoehn and Yahr stage 1-3,~* must exhibit unequivocal levodopa responsiveness~* must be able to distinguish between the off versus on state~* Subjects must be on a stable dose of levodopa for at least 28 days prior to enrollment and should be anticipated to maintain a stable dose throughout both study periods~* Subjects may be on concomitant therapy with Monoamine oxidase B inhibitors, entacapone, and amantadine, though the doses of these medications must have remained stable for at least 28 days prior to enrollment and must be expected to remain stable throughout both study periods.~Exclusion Criteria:~* History of deep brain stimulation for Parkinson Disease~* History of ablative (tissue removal) surgery for Parkinson Disease~* Presence of dementia (MMSE\<25)~* Presence of active psychosis~* History of any chronic gastrointestinal diseases~* History of any prior gastrointestinal surgeries except for appendectomy, cholecystectomy, and hysterectomy~* Any gastrointestinal surgeries in the past 3 months~* Severe dysphagia (difficulty swallowing) to pills or food~* History of physiological or mechanical gastrointestinal obstruction~* History of strictures or fistulae (abnormal or narrow connections) along the gastrointestinal tract~* History of gastric bezoars (undigested mass)~* Allergy to wheat, soy, milk, or nuts~* Presence of portable electromechanical devices such as pacemaker, defibrillator, or infusion pump~* Female subjects who are pregnant or lactating~* Symptomatic orthostatic hypotension (low blood pressure)~* Diabetes~* Presence of symptomatic anemia~* Abnormal liver or kidney function~* Cardiac arrhythmia (past or present) or abnormal QT interval on entrance EKG~* Known hypersensitivity to any of the study drugs~* Subjects receiving certain medications during specified time frames

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): One time IV dose of placebo
- Erythromycin (Type: EXPERIMENTAL): One time IV dose of 100 mg Erythromycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete